falseICU MEDICAL INC/DE000088398400008839842020-11-052020-11-05




Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 5, 2020


(Exact name of registrant as specified in its charter)
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
951 Calle Amanecer,San Clemente,California92673
(Address of principal executive offices)(Zip Code)

(949) 366-2183
Registrant's telephone number, including area code

(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common stock, par value $0.10 per shareICUIThe Nasdaq Stock Market LLC
(Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition

    ICU Medical, Inc. announced its earnings for the third quarter of 2020.
Item 9.01. Financial Statements and Exhibits.
Press release, dated November 5, 2020 announcing ICU Medical, Inc.'s third quarter 2020 earnings.
104Cover Page Interactive Data File (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 5, 2020  By: /s/ Brian M. Bonnell
   Brian M. Bonnell
   Chief Financial Officer and Treasurer


Exhibit 99.1
ICU Medical, Inc. Announces Third Quarter 2020 Results and Updates Fiscal Year 2020 Guidance
SAN CLEMENTE, Calif., November 5, 2020 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended September 30, 2020.

Third Quarter 2020 Results

Third quarter 2020 revenue was $318.6 million, compared to $307.5 million in the same period last year. GAAP gross profit for the third quarter of 2020 was $113.9 million, as compared to $118.6 million in the same period last year. GAAP gross margin for the third quarter of 2020 was 36%, as compared to 39% in the same period last year. GAAP net income for the third quarter of 2020 was $25.0 million, or $1.16 per diluted share, as compared to GAAP net income of $26.6 million, or $1.24 per diluted share, for the third quarter of 2019. Adjusted diluted earnings per share for the third quarter of 2020 were $1.90 as compared to $1.65 for the third quarter of 2019. Also, adjusted EBITDA was $62.2 million for the second quarter of 2020 as compared to $62.6 million for the third quarter of 2019.

Adjusted EBITDA and adjusted diluted earnings per share are measures calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Use of Non-GAAP Financial Information following the financial statements herein for further discussion and reconciliations of these measures to GAAP measures.

Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Third quarter results were generally in line with our expectations and reflected improved demand for our products in the U.S.”

Revenues by product line for the three and nine months ended September 30, 2020 and 2019 were as follows (in millions):
Three months ended
September 30,
Nine months ended
September 30,
Product Line20202019$ Change20202019$ Change
Infusion Consumables$116.1 $119.8 $(3.7)$350.6 $358.0 $(7.4)
Infusion Systems88.4 78.9 9.5 267.9 244.5 23.4 
IV Solutions*101.9 98.2 3.7 295.4 314.0 (18.6)
Critical Care12.2 10.6 1.6 36.7 34.2 2.5 
$318.6 $307.5 $11.1 $950.6 $950.7 $(0.1)
*IV Solutions includes $15.8 million and $44.8 million of contract manufacturing to Pfizer for the three and nine months ended September 30, 2020, respectively, as compared to $16.8 million and $61.3 million for the same periods in the prior year.

Fiscal Year 2020 Guidance Update

The Company is narrowing its 2020 outlook for adjusted EBITDA from a range of $230 million to $250 million to a range of $235 million to $245 million and updating adjusted earnings per share from a range of $5.95 to $6.65 to a range of $6.65 to $7.00.

Conference Call

The Company will host a conference call to discuss third quarter 2020 financial results on the Company, today at 4:30 p.m. EDT (1:30 p.m. PDT). The call can be accessed at (800) 936-9761, international (408) 774-4587, conference ID 9959519. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at, clicking on the Investors tab, clicking on Event Calendar and clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.

About ICU Medical, Inc.

ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells innovative medical products used in infusion therapy, and critical care applications. ICU Medical's product portfolio includes IV smart pumps, sets, connectors, closed system transfer

devices for hazardous drugs, sterile IV solutions, cardiac monitoring systems, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical, Inc. can be found at

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as ''will,'' ''expect,'' ''believe,'' ''could,'' ''would,'' ''estimate,'' ''continue,'' ''build,'' ''expand'' or the negative thereof or comparable terminology, and may include (without limitation) information regarding the Company's expectations, goals or intentions regarding the future. These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about the Company and assumptions management believes are reasonable, all of which are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, but are not limited to, decreased demand for the Company's products, decreased free cash flow, the inability to recapture conversion delays or part/resource shortages on anticipated timing, or at all, changes in product mix, increased competition from competitors, lack of growth or improving efficiencies, unexpected changes in the Company's arrangements with its largest customers and the impact of the ongoing COVID-19 pandemic on the Company and our financial results. Future results are subject to risks and uncertainties, including the risk factors, and other risks and uncertainties, described in the Company's filings with the Securities and Exchange Commission, which include those in the Company's most recent Annual Report on Form 10-K and our subsequent filings. Forward-looking statements contained in this press release are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

(In thousands)
 September 30,
December 31,
Cash and cash equivalents$350,993 $268,670 
Short-term investment securities12,544 23,967 
Accounts receivable, net of allowance for doubtful accounts 164,538 202,219 
Inventories321,961 337,640 
Prepaid income taxes8,032 15,720 
Prepaid expenses and other current assets42,071 33,981 
TOTAL CURRENT ASSETS900,139 882,197 
PROPERTY AND EQUIPMENT, net456,348 456,085 
GOODWILL32,651 31,245 
INTANGIBLE ASSETS, net200,428 211,408 
OTHER ASSETS55,795 48,984 
TOTAL ASSETS$1,729,536 $1,692,382 
Accounts payable$81,027 $128,629 
Accrued liabilities103,397 117,776 
Income tax payable935 2,063 
INCOME TAX PAYABLE16,816 14,459 
Convertible preferred stock, $1.00 par value Authorized—500 shares; Issued and outstanding— none— — 
Common stock, $0.10 par value — Authorized, 80,000 shares; Issued — 20,969 shares at September 30, 2020 and 20,743 shares at December 31, 2019 and outstanding — 20,968 shares at September 30, 2020 and 20,742 shares at December 31, 20192,097 2,074 
Additional paid-in capital683,326 668,947 
Treasury stock, at cost(180)(157)
Retained earnings782,510 721,782 
Accumulated other comprehensive loss(15,533)(15,402)
TOTAL STOCKHOLDERS' EQUITY1,452,220 1,377,244 
(1) December 31, 2019 balances were derived from audited consolidated financial statements.

(In thousands, except per share data)
Three months ended
September 30,
Nine months ended
September 30,
TOTAL REVENUES$318,567 $307,471 $950,553 $950,685 
COST OF GOODS SOLD204,643 188,919 608,930 592,961 
GROSS PROFIT113,924 118,552 341,623 357,724 
Selling, general and administrative70,854 65,876 210,401 206,333 
Research and development10,126 12,002 31,151 36,024 
Restructuring, strategic transaction and integration4,114 7,975 22,903 69,408 
Change in fair value of contingent earn-out4,300 (200)7,000 (47,400)
Contract settlement(1,000)— (975)3,822 
TOTAL OPERATING EXPENSES88,394 85,653 270,480 268,187 
INCOME FROM OPERATIONS25,530 32,899 71,143 89,537 
INTEREST EXPENSE(616)(139)(1,583)(411)
OTHER INCOME (EXPENSE), net1,252 (10)(2,175)4,660 
INCOME BEFORE INCOME TAXES26,166 32,750 67,385 93,786 
PROVISION FOR INCOME TAXES(1,180)(6,187)(6,657)(13,392)
NET INCOME$24,986 $26,563 $60,728 $80,394 
Basic$1.19 $1.29 $2.91 $3.90 
Diluted $1.16 $1.24 $2.82 $3.73 
Basic20,948 20,666 20,870 20,607 
Diluted 21,556 21,487 21,561 21,556 

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). The non-GAAP financial measures should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. There are material limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled non-GAAP financial measures used by other companies, including peer companies. Our management believes that the non-GAAP data provides useful supplemental information to management and investors regarding our performance and facilitates a more meaningful comparison of results of operations between current and prior periods. We use non-GAAP financial measures in addition to and in conjunction with GAAP financial measures to analyze and assess the overall performance of our business, in making financial, operating and planning decisions, and in determining executive incentive compensation. The non-GAAP financial measures included in this press release are adjusted EBITDA and adjusted diluted earnings per share ("Adjusted Diluted EPS").

Adjusted EBITDA excludes the following items from net income:

Interest, net: We exclude interest in deriving adjusted EBITDA as interest can vary significantly among companies depending on a company's level of income generating instruments and/or level of debt.

Stock compensation expense: Stock-based compensation is generally fixed at the time the stock-based instrument is granted and amortized over a period of several years. The value of stock options is determined using a complex formula that incorporates factors, such as market volatility, that are beyond our control. The value of our restricted stock awards is determined using the grant date stock price, which may not be indicative of our operational performance over the expense period. Additionally, in order to establish the fair value of performance-based stock awards, which are currently an element of our ongoing stock-based compensation, we are required to apply judgment to estimate the probability of the extent to which performance objectives will be achieved. Based on the above factors, we believe it is useful to exclude stock-based compensation in order to better understand our operating performance.

Intangible asset amortization expense: We do not acquire businesses or capitalize certain patent costs on a predictable cycle. The amount of purchase price allocated to intangible assets and the term of amortization can vary significantly and are unique to each acquisition. Capitalized patent costs can vary significantly based on our current level of development activities. We believe that excluding amortization of intangible assets provides the users of our financial statements with a consistent basis for comparison across accounting periods.

Depreciation expense: We exclude depreciation expense in deriving adjusted EBITDA because companies utilize productive assets of different ages and the depreciable lives can vary significantly resulting in considerable variability in depreciation expense among companies.

Restructuring, strategic transaction and integration: We incur restructuring and strategic transaction charges that result from events, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our ongoing business. Although these events are reflected in our GAAP financial statements, these unique transactions may limit the comparability of our ongoing operations with prior and future periods.

Change in fair value of contingent earn-out: We exclude the impact of certain amounts recorded in connection with business combinations. We exclude items that are either non-cash or not normal, recurring operating expenses due to their nature, variability of amounts, and lack of predictability as to occurrence and/or timing.

Product-related charges: We exclude non-cash product-related charges in determining our non-GAAP financial measures as they may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.

Contract settlement: Occasionally, we are involved in contract renegotiations that may result in one-time settlements. We exclude these settlements as they have no direct correlation to the operation of our ongoing business.

Taxes: We exclude taxes in deriving adjusted EBITDA as taxes are deemed to be non-core to the business and may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.

Adjusted Diluted EPS excludes from diluted EPS, net of tax, intangible asset amortization expense, stock compensation expense, restructuring, strategic transaction and integration, change in fair value of contingent earn-out, and contract settlement. The tax effect on the above adjustments is calculated using the specific tax rate applied to each adjustment based on the nature of the item/or the tax jurisdiction in which the item has been recorded.

From time to time in the future, there may be other items that we may exclude if we believe that doing so is consistent with the goal of providing useful information to investors and management.

The following tables reconcile our GAAP and non-GAAP financial measures:

Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
(In thousands)
 Adjusted EBITDA
Three months Ended
September 30,
GAAP net income$24,986 $26,563 
Non-GAAP adjustments:
Interest, net(142)(1,601)
Stock compensation expense6,265 3,723 
Depreciation and amortization expense21,462 19,187 
Restructuring, strategic transaction and integration4,114 7,975 
Change in fair value of contingent earn-out4,300 (200)
Contract settlement— 794 
Provision for income taxes1,180 6,187 
Total non-GAAP adjustments37,179 36,065 
 Adjusted EBITDA $62,165 $62,628 
 Adjusted diluted earnings per share
Three months ended
September 30,
 GAAP diluted earnings per share$1.16 $1.24 
 Non-GAAP adjustments:
Stock compensation expense$0.29 $0.17 
Amortization expense$0.27 $0.20 
Restructuring, strategic transaction and integration$0.19 $0.37 
Change in fair value of contingent earn-out$0.20 $(0.01)
Contract settlement$— $0.04 
Estimated income tax impact from adjustments$(0.21)$(0.36)
 Adjusted diluted earnings per share$1.90 $1.65 

ICU Medical, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP Financial Measures - Fiscal Year 2020 Outlook (Unaudited)
(In millions, except per share data)

Low End of GuidanceHigh End of Guidance
GAAP net income$73 $81 
Non-GAAP adjustments:
Interest, net(1)(1)
Stock compensation expense24 24 
Depreciation and amortization expense86 86 
Restructuring, strategic transaction and integration30 30 
Change in fair value of contingent earn-out
Contract settlement and product-related charges
Provision for income taxes11 13 
Total non-GAAP adjustments$162 $164 
Adjusted EBITDA$235 $245 
GAAP diluted earnings per share$3.41 $3.76 
Non-GAAP adjustments:
Stock compensation expense$1.11 $1.11 
Amortization expense$1.07 $1.07 
Restructuring, strategic transaction and integration$1.39 $1.39 
Change in fair value of contingent earn-out$0.32 $0.32 
Contract settlement and product-related charges$0.21 $0.21 
Estimated income tax impact from adjustments$(0.86)$(0.86)
Adjusted diluted earnings per share$6.65 $7.00 

ICU Medical, Inc.
Brian Bonnell, Chief Financial Officer
(949) 366-2183
ICR, Inc.
John Mills, Partner
(646) 277-1254